John Koreth, MBBS, PhD, Dana-Farber Cancer Institute, Boston, MA, shares an update on the latest translational and clinical advances in the field of acute graft-versus-host disease (GvHD), in particular highlighting the potential future role of itolizumab in the frontline setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.